Vertex Pharmaceuticals Inc. (VRTX) has disclosed a new risk, in the Regulation category.
Vertex Pharmaceuticals Inc. confronts a significant hurdle as the public and medical communities’ acceptance of cell and gene therapies, such as CASGEVY, remains uncertain. The company’s prosperity hinges on these therapies being embraced as necessary, cost-effective, and safe alternatives to traditional treatments. Prescribing habits of physicians, who may favor well-established treatments with more extensive clinical data, could impede the uptake of Vertex’s innovative therapies. Furthermore, potential capacity issues at medical centers and evolving public sentiment or regulatory landscapes could further challenge the commercial viability of their cell and gene therapy products.
Overall, Wall Street has a Moderate Buy consensus rating on VRTX stock based on 20 Buys, 2 Sells and 9 Holds.
To learn more about Vertex Pharmaceuticals Inc.’s risk factors, click here.
